Microstructure Imaging in Stroke Patients
Launched by DANISH RESEARCH CENTRE FOR MAGNETIC RESONANCE · Oct 7, 2019
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how advanced brain imaging techniques can help us understand the connections in the brain that may be affected after a stroke or a transient ischemic attack (TIA). One of the main goals is to learn more about why stroke patients often feel very tired, a condition known as fatigue. Researchers hope that by using these imaging tools, they can gain insights into the changes in the brain's structure that might be causing this fatigue.
To participate in this study, you need to be between the ages of 65 and 74, and you must have experienced a stroke or TIA with specific imaging results that show brain lesions. You should also have a mild level of disability, as measured by a scale that rates how well you can perform daily activities. If you qualify and decide to take part, you can expect to undergo brain imaging tests and answer questions about your fatigue. It's important to know that there are some health conditions and factors that may disqualify you from participating, so be sure to discuss any concerns with your doctor.
Gender
ALL
Eligibility criteria
- Patient Inclusion Criteria:
- • Stroke or TIA (ABCD2\>4 and/or acute Diffusion-Weighted Image (DWI) lesion).
- • Modified Rankin Scale \<=2.
- • As perceived by the investigator, have the ability to comply with all requirements of the study protocol.
- • Have the ability to understand and sign the Informed Consents Form.
- • Multidimensional Fatigue Inventory score \>= 12 on general fatigue.
- Patient Exclusion Criteria:
- • The DRCMR´s general exclusion criteria for MRI research.
- • Pregnancy or lactation; human chorionic gonadotropin (hCG) urine test is offered for women \< 55 years.
- • Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)
- • Treated with ritalin or modafinil.
- • Known uncontrolled severe malignancy.
- • Known drug or alcohol addiction.
- • Tiredness due to pharmaceutical side effects, as identified by the Investigator.
- • Max body weight of 130 kg.
- • Persons who do not wish to be informed about abnormal findings as part of the investigations.
- Healthy Controls Exclusion Criteria:
- • The DRCMR´s general exclusion criteria for MRI research.
- • Pregnancy or lactation; urin hCG test is offered for women \< 55 years.
- • Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)
- • Anamnestic infection (cystitis, influenza, pneumonia, etc) the last 3 weeks.
- • Known malignancy.
- • Known drug or alcohol addiction.
- • Tiredness due to pharmaceutical side effects.
- • Max body weight of 130 kg.
- • Persons who do not wish to be informed about abnormal findings as part of the investigations.
- Healthy Controls Inclusion Criteria:
- • Healthy
- • Age- and sex-matched to patient groups.
- • As perceived by the investigator, have the ability to comply with all requirements of the study protocol.
- • Have the ability to understand and sign the Informed Consents Form.
About Danish Research Centre For Magnetic Resonance
The Danish Research Centre for Magnetic Resonance (DRCMR) is a leading institution dedicated to advancing the field of magnetic resonance imaging (MRI) and spectroscopy through innovative research and clinical applications. With a focus on enhancing diagnostic accuracy and treatment efficacy, DRCMR collaborates with academic and industry partners to explore novel MRI techniques and technologies. The center is committed to conducting rigorous clinical trials that contribute to the understanding of various medical conditions, fostering an environment of scientific excellence and translation of research findings into clinical practice for improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Denmark
Copenhagen, Denmark
Copenhagen, København Nv, Denmark
Patients applied
Trial Officials
Tim B. Dyrby, Professor
Principal Investigator
Danish Research Centre for Magnetic Resonance
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials